Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M558Revenue (TTM) $M30.3Net Margin (%)-167.6Altman Z-Score-0.7
Enterprise Value $M451EPS (TTM) $-0.6Operating Margin %-157.7Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-167.6Higher ROA y-yN
Price/Book4.610-y EBITDA Growth Rate %-5.7Quick Ratio2.5Cash flow > EarningsY
Price/Sales14.55-y EBITDA Growth Rate %-9.3Current Ratio2.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-41.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-150.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M98.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

BCRX is held by these investors:



BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sheridan William PSenior VP - CMO 2017-11-13Sell64,310$4.7220.13view
Cohen Fred EDirector 2017-09-18Sell54,250$5.424.61view
STAAB THOMAS R IISenior Vice President and CFO 2017-03-20Sell3,250$9.2-38.37view
STAAB THOMAS R IISenior Vice President and CFO 2017-03-10Sell3,250$9.06-37.42view
STAAB THOMAS R IISenior Vice President and CFO 2017-03-08Sell6,500$8.43-32.74view
STAAB THOMAS R IISenior Vice President and CFO 2017-03-06Sell3,250$7.9-28.23view
STAAB THOMAS R IISenior Vice President and CFO 2016-12-19Sell3,250$7.45-23.89view
Barnes Alane PVP, General Counsel & Corp Sec 2016-09-14Sell8,357$4.2732.79view
Babu Yarlagadda SSenior VP - Drug Discovery 2016-08-25Sell30,000$4.0639.66view
BAKER BROS. ADVISORS LP10% Owner 2016-08-16Sell4,046,590$513.4view

Press Releases about BCRX :

Quarterly/Annual Reports about BCRX:

News about BCRX:

Articles On GuruFocus.com
BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Jan 05 2018 
BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Jan 05 2018 
BioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference Jan 03 2018 
BioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference Jan 03 2018 
Market Trends Toward New Normal in Ashland Global, BioCryst Pharmaceuticals, PICO, Chicago Rivet & M Dec 20 2017 
BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference Nov 16 2017 
BioCryst to Present at the Jefferies 2017 London Healthcare Conference Nov 01 2017 
BioCryst to Announce Third Quarter 2017 Financial Results on November 7 Oct 24 2017 
BioCryst Announces RAPIVAB® (peramivir injection) and Galidesivir Presentations at IDWeek 2017â Oct 04 2017 
BioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication Sep 21 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK